Join our daily newsletter At The Bell to receive exclusive market insights
- Living Cell Technologies (LCT) enters a trading halt as the company awaits more details in regards to an upcoming capital raise
- Trading of shares will be paused until Tuesday, May 31 or until LCT releases more information
- Earlier this week, the company announced it would apply artificial intelligence (AI) into its research to combat Parkinson’s disease
- Shares in the company last traded at 0.5 cents each on May 26
Living Cell Technologies (LCT) has entered a trading halt as the company awaits more details in regards to an upcoming capital raise.
Trading of shares will be paused until Tuesday, May 31 or until LCT releases more information.
It is not yet known how much the company is looking to raise or where the funds will be directed.
Earlier this week, the company announced it would apply artificial intelligence (AI) into its research to combat Parkinson’s disease.
It believes the use of AI will allow for highest possible quality for its NTCELL product.
Executive Chairman Professor Bernie Tuch said this is an exciting step in manufacturing the product.
“It introduces modern technology to ensure that the product released for clinical use will be of the highest standard, improving the prospects of a successful result,” he said.
Shares in the company last traded at 0.5 cents each on May 26.
